Illumination 2017 - Clayco

Illumination 2017

Project Description

The Clayco Foundation is excited to announce its Second Annual Illumination Halloween Party, raising funds to aide in the research of RVCL and other rare diseases. Building on the momentum from the success of our 2016 event, Illumination is returning for its second year on Friday October 27, 2017 at Moonlight Studios. In our inaugural year, Illumination proved itself as a one-of-a-kind Halloween celebration. In addition to raising money and awareness for a great cause, it is once again going to be the most unique Halloween event of the year.
In our first year, we raised over $400,000 for RVCL research, a condition that remains close to the hearts of our Clayco family. RVCL is a rare and fatal generic condition affecting the central nervous system, causing the deterioration of small blood vessels in the brain and eyes of those affected. Most patients begin experiencing vision loss and strokes in their early 40s. They have an average lifespan of 8 years following their first symptoms. 30 million people in the United States are living with some form of rare disease. That’s close to 1 in 10 people. Rare disease affects nearly all of us. We believe that together we can make a difference building on last year’s success. Together we are determined to find a cure for Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL.)
The Clayco Foundation is a tax exempt 501(c)(3) entity that supports multiple charitable organizations in the communities where Clayco, Inc. is actively engaged in business. Although The Clayco Foundation supports numerous charitable organizations, all of the donations raised through Illumination 2017 will directly fund research.
The funds that we raise, go to The John Atkinson Research Lab at Washington University accomplishing the following:
  • Creating the best mouse model system to determine how TREX mutations disrupt normal cellular function, understand how it works (pathophysiology) in a living system, and screen for the most effective therapeutic agents
  • Collaborating with pharmaceutical companies and the FDA to gain access to or produce a drug called aclarubicin (ACM) for human use.
  • Leading collaboration of four key research groups: Washington University in St. Louis, University of California, National Institutes of Health, and University of Texas Southwestern.
  • Planning a scientific symposium to provide enhanced data sharing, discussion of results and expansion of our knowledge base with researchers in the U.S. and globally.
This all leads to potential positive implications for:
  • Systemic Lupus Erythematosus
  • Diabetic Retinopathy
  • Aging disorders
  • Blood vessel deterioration disorders (vasculopathies)
For more information please see: